/TMCI
TMCI Stock - Treace Medical Concepts, Inc.
Healthcare|Medical - DevicesNASDAQ
$2.57+3.21%
+$0.08 (+3.21%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+81.7%upside
Target: $4.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TMCI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.54 – $2.60
TARGET (TP)$4.67
STOP LOSS$2.36
RISK/REWARD1:10.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.73
52W High$10.79
52W Low$2.43
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $209.36M | $187.12M | $141.84M | $94.42M | $57.37M |
| Gross Profit | $168.26M | $151.94M | $114.31M | $77.53M | $44.90M |
| Gross Margin | 80.4% | 81.2% | 80.6% | 82.1% | 78.3% |
| Operating Income | $-55,688,000 | $-51,428,000 | $-34,844,000 | $-16,510,000 | $855,000 |
| Net Income | $-55,743,000 | $-49,527,000 | $-42,815,000 | $-20,552,000 | $-3,668,000 |
| Net Margin | -26.6% | -26.5% | -30.2% | -21.8% | -6.4% |
| EPS | $-0.90 | $-0.81 | $-0.77 | $-0.38 | $-0.08 |
Company Overview
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
36%
Hold / Neutral
9
64%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
5 Bullish9 Neutral/Bearish
Price Targets
$14
Average Target
↑ 443.3% Upside
Now
$5
Low
$14
Average
$33
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | JP Morgan | Downgrade | Underweight | $5 |
| November 7th 2025 | BTIG Research | Downgrade | Neutral | - |
| February 4th 2025 | BTIG Research | Upgrade | Buy | $16 |
| December 31st 2024 | Lake Street | Initiation | Buy | $14.5 |
| December 17th 2024 | JP Morgan | Resumed | Neutral | $8 |
| May 16th 2024 | UBS | Downgrade | Neutral | $6.5← $16 |
| May 8th 2024 | Morgan Stanley | Downgrade | Equal Weight | $5.5← $15 |
| May 8th 2024 | Truist | Downgrade | Hold | $7← $17 |
| May 8th 2024 | Stifel | Downgrade | Hold | $6← $15 |
| May 8th 2024 | JP Morgan | Downgrade | Neutral | $8← $15 |
| May 8th 2024 | BTIG Research | Downgrade | Neutral | - |
| September 29th 2023 | UBS | Initiation | Buy | $24 |
| May 1st 2023 | Truist | Initiation | Buy | $33 |
| April 11th 2023 | Stephens | Initiation | Equal Weight | $26 |
| May 12th 2022 | BTIG Research | Initiation | Buy | $22 |
Earnings History & Surprises
TMCIBeat Rate
56%
Last 18 quarters
Avg Surprise
-118.0%
EPS vs Estimate
Beats / Misses
10/5
3 met exactly
Latest EPS
$-0.26
Q4 2025
EPS Surprise History
Q1 24
-11.1%
$-0.10vs$-0.09
Q2 24
0.0%
$-0.30vs$-0.30
Q3 24
-17.2%
$-0.34vs$-0.29
Q4 24
+7.4%
$-0.25vs$-0.27
Q1 25
+75.0%
$-0.01vs$-0.04
Q2 25
+19.4%
$-0.25vs$-0.31
Q3 25
+3.4%
$-0.28vs$-0.29
Q4 25
+7.1%
$-0.26vs$-0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.15 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.29 | $-0.34 | -17.2% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.30 | $-0.30 | 0.0% | = MET |
Q1 2024 | Feb 27, 2024 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.23 | $-0.23 | 0.0% | = MET |
Q1 2023 | Mar 7, 2023 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.01 | $-0.12 | -2300.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.12 | $-0.12 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Latest News
Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3
📉 NegativeBenzinga•Dec 18, 2025, 04:07 PM
Treace Medical Enters Into New Five Year $175M Senior Secured Loan Arrangement With Credit Funds Managed By SLR Capital Partners
➖ NeutralBenzinga•Dec 18, 2025, 01:35 PM
Truist Securities Reiterates Hold on Treace Medical Concepts, Lowers Price Target to $4
📉 NegativeBenzinga•Nov 10, 2025, 05:15 PM
UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $5.85
➖ NeutralBenzinga•Nov 7, 2025, 06:22 PM•Also:
Treace Medical plunges despite Q3 beat; BTIG downgrades on guidance cut
📉 NegativeSeeking Alpha•Nov 7, 2025, 04:42 PM
JP Morgan Downgrades Treace Medical Concepts to Underweight, Lowers Price Target to $5
📉 NegativeBenzinga•Nov 7, 2025, 12:20 PM
Treace Medical Concepts shares are trading lower after the company reported Q3 financial results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 7, 2025, 11:57 AM
BTIG Downgrades Treace Medical Concepts to Neutral
➖ NeutralBenzinga•Nov 7, 2025, 11:03 AM
Treace Medical Concepts shares are trading lower after the company reported Q3 financial results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 6, 2025, 09:48 PM
Treace Medical Concepts Lowers FY2025 Sales Guidance from $224.000M-$230.000M to $211.000M-$213.000M vs $227.083M Est
📉 NegativeBenzinga•Nov 6, 2025, 09:11 PM
Treace Medical Concepts Q3 EPS $(0.26) Beats $(0.28) Estimate, Sales $50.214M Beat $49.732M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:10 PM
Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $7
📉 NegativeBenzinga•Oct 15, 2025, 04:03 PM
Treace Showcases Expanded Bunion Surgery Portfolio And Positive ALIGN3D & MTA3D Clinical Data At 2025 AOFAS Annual Meeting
📈 PositiveBenzinga•Sep 10, 2025, 11:23 AM
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $8
➖ NeutralBenzinga•Sep 4, 2025, 12:27 PM
Frequently Asked Questions about TMCI
What is TMCI's current stock price?
Treace Medical Concepts, Inc. (TMCI) is currently trading at $2.57 per share. The stock has moved +3.21% today.
What is the analyst price target for TMCI?
The average analyst price target for TMCI is $4.67, based on 1 analyst.
What sector is Treace Medical Concepts, Inc. in?
Treace Medical Concepts, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is TMCI's market cap?
Treace Medical Concepts, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does TMCI pay dividends?
No, Treace Medical Concepts, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBVS
Bioventus Inc.
$7.49
Mkt Cap: $0.5B
CBLL
CeriBell, Inc.
$21.20
Mkt Cap: $0.8B
EHAB
Enhabit, Inc.
$9.56
Mkt Cap: $0.5B
EOLS
Evolus, Inc.
$7.07
Mkt Cap: $0.5B
KIDS
OrthoPediatrics Corp.
$17.07
Mkt Cap: $0.4B
LAB
Standard BioTools Inc.
$1.63
Mkt Cap: $0.6B
RXST
RxSight, Inc.
$12.03
Mkt Cap: $0.5B
SMLR
Semler Scientific, Inc.
$17.93
Mkt Cap: $0.3B
SRDX
Surmodics, Inc.
$42.98
Mkt Cap: $0.6B
TOI
The Oncology Institute, Inc.
$3.50
Mkt Cap: $0.3B
Explore stocks similar to TMCI for comparison